Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ribozyme: a clinical tool.

Asad U Khan1

  • 1Interdisciplinary Biotechnology unit, Aligarh Muslim University, Aligarh 202002, India. huzzi99@hotmail.com

Clinica Chimica Acta; International Journal of Clinical Chemistry
|January 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor-stromal signaling.

Cell death & disease·2026
Same author

Editorial: Breaking the biofilm barrier: analysis of molecular mechanisms underlying biofilm formation and identification of novel antimicrobial approaches.

Frontiers in microbiology·2026
Same author

Multidrug-resistant Escherichia coli ST940 carrying bla<sub>NDM-7</sub> on a Mosaic IncFIA/IncFIB/IncFII plasmid recovered from wastewater.

Molecular biology reports·2026
Same author

Ciprofloxacin-functionalized silver nanocomposite: a promising strategy against colistin-resistant Pseudomonas aeruginosa.

Letters in applied microbiology·2026
Same author

T6SS mutants exploit itaconate to support infection of phagocytes.

bioRxiv : the preprint server for biology·2026
Same author

A mutation-aware proteomics approach for designing a multi-epitope vaccine against multidrug-resistant <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i>.

Microbiology spectrum·2026
Same journal

Comparing conventional correction formulas and machine learning-based prediction of ionized calcium.

Clinica chimica acta; international journal of clinical chemistry·2026
Same journal

Micro- and nanoplastics as emerging clinical analytes: analytical validation, interpretive uncertainty, and laboratory actionability in human specimens.

Clinica chimica acta; international journal of clinical chemistry·2026
Same journal

Performance of Free Light Chain reagents in the Dutch External Quality Assessment programme over the past 14 years.

Clinica chimica acta; international journal of clinical chemistry·2026
Same journal

CRISPR-Cas12a-based liquid biopsy technology: challenges in large-scale clinical application.

Clinica chimica acta; international journal of clinical chemistry·2026
Same journal

Diagnostic biomarkers, prognostic signatures, and therapeutic resistance: shedding light on the dual role of autophagy in glioblastoma.

Clinica chimica acta; international journal of clinical chemistry·2026
Same journal

Artificial intelligence in diagnostic software: validation, safety, and lifecycle challenges in Europe.

Clinica chimica acta; international journal of clinical chemistry·2026
See all related articles

Catalytic RNAs, or ribozymes, show promise as antiviral and anti-cancer therapies by inhibiting gene expression. Further research is needed to optimize their stability, delivery, and long-term efficacy in biological systems.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Gene Therapy

Background:

  • Catalytic RNAs (ribozymes) possess specific RNA-cleaving abilities.
  • Ribozymes are explored for therapeutic applications, including antiviral and anti-cancer treatments.
  • Successful gene expression inhibition has been demonstrated in vitro and in vivo.

Purpose of the Study:

  • To review the structure, catalysis, and therapeutic potential of ribozymes.
  • To highlight the application of ribozymes in functional genomic studies.
  • To discuss advancements and challenges in ribozyme-based therapies.

Main Methods:

  • Review of existing literature on ribozyme structure and function.
  • Analysis of studies demonstrating ribozyme efficacy in gene expression inhibition.

Related Experiment Videos

  • Examination of clinical trial data for ribozyme gene therapy.

    • Main Results:

    • Ribozymes have shown success in inhibiting gene expression in various biological systems.
    • Phase I clinical trials for AIDS treatment using ribozyme gene therapy have been initiated.
    • Significant challenges remain in optimizing ribozyme stability, activity, and delivery.

    Conclusions:

    • Ribozymes offer a promising platform for developing novel therapeutic agents.
    • Further investigation is crucial for overcoming challenges in cellular stability, in vivo activity, target identification, and tissue-specific delivery.
    • Continued research will advance the clinical application of ribozymes for treating diseases like AIDS.